Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial

Cancer

Volumn 78, Issue 7, 1996, Pages 1452-1460

  Emons, Günter ^a   Ortmann, Olaf ^a   Teichert, Hanns Martin ^b   Fassl, Horst ^b   Löhrs, Udo ^c   Kullander, Stig ^d   Kauppila, Antti ^e   Ayalon, Daniel ^f   Schally, Andrew ^g   Oberheuser, Friedhelm ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF OULU   (Finland)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytoreductive surgery; cytotoxic chemotherapy; luteinizing hormone releasing hormone agonist; ovarian cancer; suppression of gonadotrophins

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DECAPEPTYL DEPOT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GONADORELIN AGONIST; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; TREOSULFAN; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DOUBLE-BLIND METHOD; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRIPTORELIN;

EID: 10144237848     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961001)78:7<1452::AID-CNCR12>3.0.CO;2-Z     Document Type: Article

References (42)

1. Ozols RF, Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez SA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott, 1992:731-81.
2. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55:591-6.
3. Stewart LA, for the Advanced Ovarian Cancer Trialist Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991;303:884-93.
4. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994;55:S143-50.
5. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment and follow-up. Gynecol Oncol 1994;55:S4-14.
6. Neijt IP. Advances in the chemotherapy of gynecologic cancer. Curr Opin Oncol 1994;6:531-8.
7. Kaldor JM, Day NE, Petterson F, Clarke EA, Pedersen D, Mehnert W, et al. Leukemia following chemotherapy for ovarian cancer. New Engl J Med 1990;322:1-6.
8. Cheruku R, Hussain M, Tyrkus M, Edelstein M. Myelodysplastic syndrome after cisplatin therapy. Cancer 1993; 72:213-8.
9. Colon-Otero G, Malkasian GP, Edmonson JH. Secondary myelodysplasia and acute leukemia following carboplatin-containing chemotherapy for ovarian cancer. J Natl Cancer Inst 1993;85:1858-60.
10. Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26.
11. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod 1994;9:1364-79.
12. Mortel R, Satyaswaroop PG, Schally AV, Hamilton T, Ozols R. Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH:OVCAR-3 in the nude mouse. Gynecol Oncol 1986;23:254-5.
13. Peterson CM, Zimniski SJ. A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet Gynecol 1990;76:264-7.
14. 6LHRH. Cancer Treat Rep 1985;69:1341-2.
15. Kullander S, Rausing A, Schally AV. LH-RH agonist treatment in ovarian cancer. In: Klijn JGM, editor. Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. New York: Raven Press, 1987:353-6.
16. 6-luteinizing hormone-releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. BMJ 1988;296:1229.
17. 6LH-RH (Decapeptyl) microcapsules. Biochem Pharmacother 1988;42:531-8.
18. Jäger W, Wildt L, Lang N. Some observations on the effects of a GnRH analog in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1989;32:137-48.
19. Bruckner HW, Motwani BT. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol 1989;161:1216-8.
20. Kavanagh JJ, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989;7:115-8.
21. Vavra N, Barrada M, Fitz R, Sevelda P, Baur M, Dittrich C. Goserelin - eine neue Form der Hormontherapie beim Ovarialkarzinom. Gynäkol Rundsch 1990;30 (Suppl 1):61-3.
22. Lind MJ, Cantwell BMJ, Millward MJ, Robinson A, Proctor M, Simmons D, et al. A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 1992; 65:621-3.
23. van der Burg MEL, ten Bokkel Huinink WW, Kobiersky A, Namer M, Vermorken JB, Tumolo S, et al. Chemotherapy and hormonal treatment in ovarian cancer: experiences of the EORTC gynecological cancer cooperative group. In: Meerphol HG, Pfleiderer A, Profous CZ, editors. Das Ovarialkarzinom. Volume 2. Berlin, Heidelberg, New York: Springer, 1993:114-31.
24. Gehan EA. Statistical methods for survival time studies. In: Cancer therapy: Prognostic factors and criteria. New York: Raven Press, 1975:7-35. (Cited from: SPSS Statistical Algorithms. 2nd edition. Chicago: SPSS Inc, 1991.)
25. Gehan EA. Statistical methods for survival time studies. In: Cancer therapy: Prognostic factors and criteria. New York: Raven Press, 1975:7-35. (Cited from: SPSS Statistical Algorithms. 2nd edition. Chicago: SPSS Inc, 1991.)
26. Lee E, Desu M. A computer program for comparing k samples with right censored data. Comput programs in biomed 1972:315-21. (Cited from: SPSS Statistical Algorithms. 2nd edition. Chicago: SPSS Inc., 1991.)
27. Lee E, Desu M. A computer program for comparing k samples with right censored data. Comput programs in biomed 1972:315-21. (Cited from: SPSS Statistical Algorithms. 2nd edition. Chicago: SPSS Inc., 1991.)
28. Lachin JM. Introduction to sample size determination and analysis for clinical trials. Control Clin Trials 1981;2:93-113.
29. Creasman WT. Second look laparatomy in ovarian cancer. Gynecol Oncol 1994;55:S122-7.
30. Schwartz PE, Chambers JT, Kohorn EJ, Chambers SK, Weitzman H, Voynick JM, et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. Cancer 1989;63:1074-8.
31. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 1991;68:269-71.
32. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokick JJ, Sinclair PR, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993;11:1957-68.
33. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340:329-33.
34. Erickson LD, Hartmann LC, Su JQ, Nielsen SNJ, Pfeifel DM, Goldberg RM, et al. Cyclophosphamide, cisplatin and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. Gynecol Oncol 1994;54:196-200.
35. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, et al. High affinity binding and direct antiproliferative effects of LH-RH analogues in human ovarian cancer cell lines. Cancer Res 1993;54:5439-46.
36. Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, et al. Expression of the messenger ribonucleic acids for luteinizing hormone releasing hormone and its receptors in human ovarian epithelial carcinoma. Cancer Res 1995; 55:817-22.
37. Ohno T, Imai A, Furui T, Takahashi K, Tamaya T. Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma. Am J Obstet Gynecol 1993;163:605-10.
38. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Gonadotropin-releasing hormone receptor in gynecologic tumors. Cancer 1994;74:2555-61.
39. Yano T, Pinski J, Radulovic S, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 1994;91:1701-4.
40. Thompson MA, Adelson MD, Kaufman LM. Lupron retards proliferation of ovarian tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 1991;72:1036-41.
41. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A 1994;91:7090-4.
42. Janaky T, Juhasz A, Bajusz S, Czernus V, Srkalovic G, Bokser L, et al. Analogues of luteinizing hormone releasing hormone containing cytotoxic groups. Proc Natl Acad Sci U S A 1992;89:972-6.